FGFR2 and cholangiocarcinoma: Overall, confirmed partial response (PR) was observed in two patients per investigator assessments, including one patient with FGFR1-mutant (p.A354V) esophageal carcinoma and one with FGFR2-mutant (p.F276C) CCA (Fig. 2), which contributed to an ORR of 16.7% (95% confidence interval [CI], 2.1%–48.4%; Supplement Table S1).